AMPH
NASDAQAmphastar Pharmaceuticals Inc.
Price$20.54+0.33 (+1.63%)
01:30 PM07:45 PM
News · 26 weeks500%
2025-12-142026-06-07
Mix2590d
- Insider10(40%)
- SEC Filings6(24%)
- Market5(20%)
- Analyst3(12%)
- Other1(4%)
Latest news
25 items- INSIDERDirector Prins Richard K gifted 1,500 shares and was granted 8,143 shares, increasing direct ownership by 21% to 37,598 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERDirector Lee Howard covered exercise/tax liability with 769 shares and was granted 8,143 shares, increasing direct ownership by 5% to 159,350 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERDirector Zasloff Michael A was granted 8,143 shares, increasing direct ownership by 28% to 37,667 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERDirector Gerst Diane G. was granted 8,143 shares, increasing direct ownership by 34% to 31,899 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERDirector Gaugh David Russell was granted 8,143 shares, increasing direct ownership by 129% to 14,447 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERDirector Deflin Gayle was granted 8,143 shares, increasing direct ownership by 75% to 19,057 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- SECAmphastar Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
- NEWSAmphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal p
- ANALYSTAmphastar Pharmaceuticals downgraded by Wells Fargo with a new price targetWells Fargo downgraded Amphastar Pharmaceuticals from Overweight to Equal Weight and set a new price target of $19.00
- ANALYSTAmphastar Pharmaceuticals downgraded by NeedhamNeedham downgraded Amphastar Pharmaceuticals from Buy to Hold
- SECSEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
- SECAmphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
- NEWSAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026Net revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarterCompany to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026."In the first quart
- NEWSAmphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care ConferenceRANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, a
- NEWSAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll-free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live
- ANALYSTAmphastar Pharmaceuticals downgraded by Jefferies with a new price targetJefferies downgraded Amphastar Pharmaceuticals from Buy to Hold and set a new price target of $22.00
- SECSEC Form DEFA14A filed by Amphastar Pharmaceuticals Inc.DEFA14A - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
- SECSEC Form DEF 14A filed by Amphastar Pharmaceuticals Inc.DEF 14A - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
- NEWSAmphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare ConferenceRANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar Pharmaceuticals, Inc.Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.SCHEDULE 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
- INSIDEREVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERSENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERCFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- INSIDERCEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. covered exercise/tax liability with 12,692 shares, decreasing direct ownership by 0.33% to 2,990,052 units (SEC Form 4)4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
- SECAmphastar Pharmaceuticals Inc. filed SEC Form 8-K: Other Events8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
AMPH FAQ
7 questionsWhat does Amphastar Pharmaceuticals Inc. do?
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection...Where does AMPH stock trade?
Amphastar Pharmaceuticals Inc. (AMPH) is listed on NASDAQ.What sector and industry is AMPH in?
Amphastar Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Amphastar Pharmaceuticals Inc. go public?
Amphastar Pharmaceuticals Inc. (AMPH) completed its IPO in 2014.What are analysts saying about AMPH?
Amphastar Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1900.00 price target on 2026-05-14. Recent price targets range from $1900.00 to $3600.00.What companies are similar to AMPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AMPH side-by-side with any of them on Quantisnow.How can I track AMPH on Quantisnow?
Quantisnow aggregates Amphastar Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMPH to receive live email and push alerts on every new disclosure.